A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
Active, not recruitingCTIS2022-501622-37-00
Celltrion Inc.Multiple Sclerosis
Start: 2024-01-16Target: 432Updated: 2025-07-28